Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: 8 - You Need To See This

Someone with a lot of money to spend has taken a bullish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Looking At AbbVie's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 12 strange trades.

Benzinga

Looking At AbbVie's Recent Whale Trades

Someone with a lot of money to spend has taken a bearish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Illinois Senate President Don Harmon, other pols keep taking money from pharma companies implicated in opioid crisis

The Oak Park Democrat continues to accept campaign money from Johnson & Johnson, 1 of 4 companies paying $26 billion to settle suits accusing them of fueling the crisis. He’s not the only Illinois official doing so.

Chicago Sun-Times

4 "Strong Buy" Stocks for a Fear-Driven Market

Even though the inflation declined slightly from the 40-year high in July, it stayed elevated. Therefore, the Fed could maintain its hawkish stance on tightening monetary policy, which will drive market volatility. Amid this fear-driven market, we think it could be prudent to invest in fundamentally sound stocks AbbVie (ABBV),…

StockNews.com

Looking At AbbVie's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 12 strange trades.

Benzinga

Recession Investing: 5 High Yield Dividend Stocks For A Downturn

As the healthcare industry absorbed enormous amounts of profits during the Covid-19 pandemic, many healthcare companies will be increasing shareholder distributions to entice investors to buy their stock.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

3 Stocks to Help You Survive and Thrive in Today's Market

Growing concerns over sky-high inflation, the Fed’s aggressive interest rate hikes, the decline in GDP for two consecutive quarters, and increasing odds of a recession are expected to keep the stock market under tremendous pressure in the near term. Amid this backdrop, investing in fundamentally sound stocks AbbVie (ABBV), Acuity…

StockNews.com

Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Recap Of Friday's Biotech Catalysts - End of The Day Summary

The U.S. Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ (NASDAQ:ARQT) New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for the treatment of plaque psoriasis in patients 12 years of age or older. The company expects commercial launch of the product in Mid-August. Arcutis shares traded in a range of…

Benzinga

What Are Whales Doing With AbbVie

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 18 strange trades.

Benzinga

Direct-acting antivirals can cure hepatitis C and prisons are now leading efforts to eliminate the virus

While most medical attention has been on COVID, work has been underway to eliminate another viral disease, hepatitis C.

The Conversation

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical trial collaboration and supply agreement with Amgen Inc. to evaluate the efficacy and safety of IDE397 with Amgen's AMG 193 in a Phase 1 clinical trial. IDEAYA shares traded in a range of $14.59 to $15.82 on a day volume of 130.58…

Benzinga

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Recap of Wednesday's Biotech Catalysts - End of The Day Summary

Benzinga

Recap of Monday's Biotech Catalysts - End of the Day Summary

Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month.

Benzinga

AbbVie Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 10 strange trades.

360info

Less talk, more action needed to reform IP for all

IP laws are supposed to work to aid pharmaceutical innovation in rich nations. Can a new system support treating illnesses rife in developing economies, too?

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Benzinga Before The Bell: Elon Musk's Kids, Apple's Potential Security Measure, Covid-19 Vaccine Wastage And Other Top Financial Stories Thursday, July 7

CNBC

Benzinga

Check Out What Whales Are Doing With ABBV

Benzinga

Analyzing AbbVie's Short Interest

AbbVie's (NYSE:ABBV) short percent of float has risen 27.78% since its last report. The company recently reported that it has 13.52 million shares sold short, which is 0.92% of all regular shares that are available for trading.

Benzinga

If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 6.01% on an annualized basis producing an average annual return of 15.88%. Currently, AbbVie has a market capitalization of $267.24 billion.

Benzinga

AbbVie Whale Trades Spotted

Benzinga

Recap of Tuesday's Biotech Catalysts - End of the Day Summary

Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) Ionis shares are trading low 4 percent at $35.10 in the after-hours session

Benzinga

Why AbbVie Stock Is Trading Higher Today

AbbVie Inc (NYSE: ABBV) shares are trading higher Tuesday after the company announced it submitted a supplemental New Drug Application for atogepant to the U.S. Food and Drug Administration to support the preventive treatment of chronic migraine in adults.

1 … 7 8 9 10

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Intellectual Property

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.